Current Hepatitis Reports

, Volume 9, Issue 2, pp 119–123

Treatment of Acute Hepatitis B with Nucleoside and/or Nucleotide Analogues



Acute infection with the hepatitis B virus resolves in 95% of adults with no need for specific medical therapy. However, a few cases present as severe hepatitis or acute liver failure, which may require orthotopic liver transplantation or cause death. Under these circumstances, medical therapy that can improve the clinical outcome and improve spontaneous survival would be highly useful; yet, published data regarding the utility of antiviral therapy in acute hepatitis B is quite limited. In this paper, the efficacy and safety of oral nucleoside and nucleotide analogues in the treatment of acute hepatitis B are reviewed, and guidelines for treatment of these acute cases are revisited.


Acute hepatitis Nucleotide analogue Nucleoside analogue Lamivudine Entecavir Telbivudine Adefovir Tenofovir Therapy Fulminant hepatic failure 


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Daniels D, Grytdal S, Wasley A; Centers for Disease Control and Prevention (CDC): Surveillance for acute viral hepatitis—United States, 2007. MMWR Surveill Summ 2009, 58(3):1–27.PubMedGoogle Scholar
  2. 2.
    Schiødt FV, Davern TJ, Shakil AO, et al.: Viral hepatitis-related acute liver failure. Am J Gastroenterol 2003, 98:448–453.PubMedGoogle Scholar
  3. 3.
    Tassopoulos NC, Koutelou MG, Polychronaki H, et al.: Recombinant interferon-alpha therapy for acute hepatitis B: a randomized, double-blind, placebo-controlled trial. J Viral Hepat 1997, 4:387–394.CrossRefPubMedGoogle Scholar
  4. 4.
    Kundu SS, Kundu AK, Pal NK: Interferon-alpha in the treatment of acute prolonged hepatitis B virus infection. J Assoc Physicians India 2000, 48:671–673.PubMedGoogle Scholar
  5. 5.
    Flink HJ, Sprengers D, Hansen BE, et al.: Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy. Gut 2005, 54:1604–1609.CrossRefPubMedGoogle Scholar
  6. 6.
    Perrillo RP: Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001, 120:1009–1022.CrossRefPubMedGoogle Scholar
  7. 7.
    Baumert TF, Thimme R, von Weizsäcker F: Pathogenesis of hepatitis B virus infection. World J Gastroenterol 2007, 13:82–90.PubMedGoogle Scholar
  8. 8.
    Leifeld L, Cheng S, Ramakers J, et al.: Imbalanced intrahepatic expression of interleukin 12, interferon gamma, and interleukin 10 in fulminant hepatitis B. Hepatology 2002, 36:1001–1008.PubMedGoogle Scholar
  9. 9.
    Hoofnagle JH, di Bisceglie AM: The treatment of chronic viral hepatitis. N Engl J Med 1997, 336:347–356.CrossRefPubMedGoogle Scholar
  10. 10.
    Manns MP: Current state of interferon therapy in the treatment of chronic hepatitis B. Semin Liver Dis 2002, 22(Suppl 1):7–13.CrossRefPubMedGoogle Scholar
  11. 11.
    Lok AS, Lai CL, Leung N, et al.: Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003, 125:1714–1722.CrossRefPubMedGoogle Scholar
  12. 12.
    Reshef R, Sbeit W, Tur-Kaspa R: Lamivudine in the treatment of acute hepatitis B. N Engl J Med 2000, 343:1123–1124.CrossRefPubMedGoogle Scholar
  13. 13.
    Chalupa P, Holub M: Favorable outcome of severe acute hepatitis B in a patient treated with antithrombin III and antiviral therapy. Clin Infect Dis 2009, 49:481.CrossRefPubMedGoogle Scholar
  14. 14.
    Torii N, Hasegawa K, Ogawa M, et al.: Effectiveness and long-term outcome of lamivudine therapy for acute hepatitis B. Hepatol Res 2002, 24:34.CrossRefPubMedGoogle Scholar
  15. 15.
    Kondili LA, Osman H, Mutimer D: The use of lamivudine for patients with acute hepatitis B (a series of cases). J Viral Hepat 2004, 11:427–431.CrossRefPubMedGoogle Scholar
  16. 16.
    Petrelli E, Balducci M, Pieretti C, et al.: Lamivudine treatment failure in preventing fatal outcome of de novo severe acute hepatitis B in patients with haematological diseases. J Hepatol 2001, 35:823–826.CrossRefPubMedGoogle Scholar
  17. 17.
    Wang YC, Kuo MC, Hung CC, et al.: Lamivudine reverses severe acute hepatitis B and pancytopenia after renal transplantation: a case report. Transplant Proc 2006, 38:3125–3127.CrossRefPubMedGoogle Scholar
  18. 18.
    Haznedar R, Yağci M.: Lamivudine therapy for acute hepatitis B infection following peripheral blood stem cell transplantation. Am J Hematol 2002, 69:151.CrossRefPubMedGoogle Scholar
  19. 19.
    Nakhoul F, Gelman R, Green J, et al.: Lamivudine therapy for severe acute hepatitis B virus infection after renal transplantation: case report and literature review. Transplant Proc 2001, 33:2948–2949.CrossRefPubMedGoogle Scholar
  20. 20.
    Andreone P, Caraceni P, Grazi GL, et al.: Lamivudine treatment for acute hepatitis B after liver transplantation. J Hepatol 1998, 29:985–989.CrossRefPubMedGoogle Scholar
  21. 21.
    Efremov DG, Georgievski B, Cevreska L, et al.: Lamivudine treatment for acute hepatitis B virus infection during allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2003, 31:515–516.CrossRefPubMedGoogle Scholar
  22. 22.
    Dulai G, Higa L, Kobashigawa J, Martin P: Successful use of lamivudine for severe acute hepatitis B virus infection in a cardiac transplant recipient. Transplantation 1999, 67:1288–1289.CrossRefPubMedGoogle Scholar
  23. 23.
    Gupta S, Piraka C, Jaffe M: Lamivudine in the treatment of polyarteritis nodosa associated with acute hepatitis B. N Engl J Med 2001, 344:1645–1646.CrossRefPubMedGoogle Scholar
  24. 24.
    Di Marco V, De Lisi S, Li Vecchi M, et al.: Therapy with lamivudine and steroids in a patient with acute hepatitis B and rapidly progressive glomerulonephritis. Kidney Int 2006, 70:1187–1188.CrossRefPubMedGoogle Scholar
  25. 25.
    Miyake Y, Iwasaki Y, Takaki A, et al.: Lamivudine treatment improves the prognosis of fulminant hepatitis B. Intern Med 2008, 47:1293–1299.CrossRefPubMedGoogle Scholar
  26. 26.
    Lisotti A, Azzaroli F, Buonfiglioli F, et al.: Lamivudine treatment for severe acute HBV hepatitis. Int J Med Sci 2008, 5:309–312.PubMedGoogle Scholar
  27. 27.
    Delic D, Nesic Z, Prostran M, et al.: Treatment of subacute hepatitis B with lamivudine: a pilot study in Serbia. Vojnosanit Pregl 2009, 66:199–202.PubMedGoogle Scholar
  28. 28.
    Schmilovitz-Weiss H, Ben-Ari Z, Sikuler E, et al.: Lamivudine treatment for acute severe hepatitis B: a pilot study (published erratum appears in Liver Int 2004, 24:547–551). Liver Int 2004, 24:547–551.CrossRefPubMedGoogle Scholar
  29. 29.
    Tillmann HL, Hadem J, Leifeld L, et al.: Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat 2006, 13:256–263.CrossRefPubMedGoogle Scholar
  30. 30.
    • Kumar M, Satapathy S, Monga R, et al.: A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology 2007, 45:97–101. This article describes the largest prospective study that evaluated lamivudine therapy in acute hepatitis B, with other larger studies being references 28 and 29.CrossRefPubMedGoogle Scholar
  31. 31.
    Girke J, Wedemeyer H, Wiegand J, et al.: Acute hepatitis B: is antiviral therapy indicated? Two case reports [article in German]. Dtsch Med Wochnschr 2008, 133:1178–1182.CrossRefGoogle Scholar
  32. 32.
    • Palumbo E: Entecavir for chronic hepatitis B: a review. Ther Drug Monit 2008, 30:1–4. This article is a comprehensive review of entecavir, its safety and efficacy, as a treatment for hepatitis B.CrossRefPubMedGoogle Scholar
  33. 33.
    • Lange CM, Bojunga J, Hofmann WP, et al.: Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009, 50:2001–2006. This article is a report of severe lactic acidosis in a case series of patients with hepatitis B cirrhosis and significantly impaired liver function while on entecavir therapy.CrossRefPubMedGoogle Scholar
  34. 34.
    •• Lok AS, McMahon BJ: Chronic hepatitis B: update 2009. Hepatology 2009, 50:661–662. This article is an updated set of practice guidelines that provide a comprehensive guide to the management of hepatitis B in various populations.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.University of Chicago Medical CenterChicagoUSA

Personalised recommendations